Last reviewed · How we verify
Placebo IV Infusion
Placebo IV infusion contains no active pharmaceutical ingredient and produces therapeutic effects primarily through the placebo effect.
Placebo IV infusion contains no active pharmaceutical ingredient and produces therapeutic effects primarily through the placebo effect. Used for Used as a control arm in phase 3 clinical trials (specific indication depends on the active comparator drug being tested).
At a glance
| Generic name | Placebo IV Infusion |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
A placebo is an inert substance administered in a clinical trial or therapeutic context that lacks pharmacological activity. The apparent clinical benefit derives from patient expectation, the therapeutic ritual of administration, and natural disease progression rather than direct molecular action. Placebo IV infusions are typically used as control comparators in randomized controlled trials to establish the efficacy of active investigational drugs.
Approved indications
- Used as a control arm in phase 3 clinical trials (specific indication depends on the active comparator drug being tested)
Common side effects
- Adverse events attributable to placebo effect or infusion procedure (e.g., injection site reactions, mild discomfort)
Key clinical trials
- A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) (PHASE3)
- Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma (PHASE3)
- MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) (PHASE3)
- A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) (PHASE3)
- A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade (PHASE2)
- Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE) (PHASE3)
- Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo IV Infusion CI brief — competitive landscape report
- Placebo IV Infusion updates RSS · CI watch RSS
- Pfizer portfolio CI